Journal Health of Woman. 2026. 3(184): 20-28. doi: 10.15574/HW.2026.3(184).2028

Yakimchuk Y. B., Boychuk A. V.
I. Horbachevsky Ternopil National Medical University, Ukraine

For citation: Yakimchuk YB, Boychuk AV. (2026). Prevention of post-biopsy complications: bleeding control, reduction of infection risk and support of cervical healing. Ukrainian Journal Health of Woman. 3(184): 20-28. doi: 10.15574/HW.2026.3(184).2028
Article received: Mar 07, 2026. Accepted for publication: Jun 01, 2026.

Despite the minimally invasive nature of colposcopy-directed cervical biopsy, the procedure results in a localized cervical wound that may be associated with post-biopsy complications. This supports the need to optimize post-procedural management aimed at controlling bleeding, reducing the risk of infectious and inflammatory complications, and supporting cervical epithelialization.
Aim – to evaluate the clinical effectiveness of a comprehensive approach to the prevention of post-biopsy cervical complications by supplementing standard management with local application of the policresulen-containing medical device Vagipur.
Materials and methods. An open-label comparative study was conducted in 60 women of reproductive age with cervical intraepithelial lesions who underwent colposcopy-directed cervical biopsy. The patients were divided into two groups of 30 participants each: Group I received standard post-biopsy management, whereas Group II additionally received Vagipur administered vaginally as one suppository at bedtime for 5 consecutive days. Post-biopsy bleeding, vaginal symptoms, adverse events, treatment satisfaction, and changes in colposcopic findings at 3 months were assessed.
Results. The addition of the medical device Vagipur to standard post-biopsy management was associated with a more rapid reduction in bleeding and a lower cumulative bleeding score. In Group II, marked improvement in vaginal symptoms at Day 10, clinical cure of bacterial vaginosis, higher treatment satisfaction, and favorable changes in colposcopic findings according to the Swede score at 3 months were observed more frequently. Local adverse events were reported more frequently in Group II; however, none resulted in treatment discontinuation, and no allergic reactions were recorded.
Conclusions. Comprehensive post-biopsy management with the medical device Vagipur contributed to better bleeding control, improvement in vaginal symptoms, a higher rate of clinical cure of bacterial vaginosis, and more favorable changes in colposcopic findings after colposcopy-directed cervical biopsy.
The study was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants.
The authors declare no conflicts of interest.
Keywords: cervical biopsy, post-biopsy complications, bleeding, infection risk, bacterial vaginosis, policresulen, Vagipur, colposcopy, epithelialization, human papillomavirus.

REFERENCES

1. American College of Obstetricians and Gynecologists. Committee on Gynecologic Practice. (2020, Oct). Topical Hemostatic Agents at Time of Obstetric and Gynecologic Surgery: ACOG Committee Opinion, Number 812. Obstet Gynecol. 136(4): e81-e89. https://doi.org/10.1097/AOG.0000000000004104; PMid:32976379

2. Bornstein J, Bentley J, Bösze P, Girardi F, Haefner H, Menton M et al. (2012). 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol. 120(1): 166-172. https://doi.org/10.1097/AOG.0b013e318254f90c; PMid:22914406

3. Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D et al. (2023). Human Papillomavirus and Related Diseases in Ukraine. Summary Report 10 March 2023. ICO/IARC HPV Information Centre. URL: https://hpvcentre.net/statistics/reports/UKR.pdf.

4. Cheu RK, Mohammadi A, Schifanella L, Broedlow C, Driscoll CB, Miller CJ et al. (2022). Altered innate immunity and damaged epithelial integrity in vaginal microbial dysbiosis. Front Reprod Health. 4: 876729. https://doi.org/10.3389/frph.2022.876729; PMid:36303633 PMCid:PMC9580658

5. Chong GO, Lee YH, Jeon SY et al. (2020). Efficacy of a chitosan tampon in the loop electrosurgical excision procedure: A prospective randomized controlled study. Sci Rep. 10: 6017. https://doi.org/10.1038/s41598-020-62965-1; PMid:32265495 PMCid:PMC7138841

6. Cohen PA, Jhingran A, Oaknin A, Denny L. (2019). Cervical cancer. Lancet. 393(10167): 169-182. https://doi.org/10.1016/S0140-6736(18)32470-X; PMid:30638582

7. Espitia-De-La-Hoz FJ. (2021). Evaluación de la eficacia y seguridad del policresuleno en el tratamiento de la vaginitis mixta, Armenia, Colombia, 2017-2019. Estudio aleatorizado. Archivos de Medicina. 21(1): 45-56. https://doi.org/10.30554/archmed.21.1.3756.2021

8. European Commission: Directorate-General for Health and Food Safety, Anttila A, Arbyn M, De Vuyst H, Dillner J et al. (eds). (2015). European guidelines for quality assurance in cervical cancer screening. Second edition. Supplements, Publications Office. URL: https://data.europa.eu/doi/10.2875/859507.

9. Feng X, Song W, Ren X, Xu Z, Li C et al. (2025). Microbial influences on HPV infection and cervical carcinogenesis: emerging evidence from the vaginal microbiome. Front Microbiol. 16: 1733315. https://doi.org/10.3389/fmicb.2025.1733315; PMid:41477198 PMCid:PMC12748193

10. Gillet E, Meys JF, Verstraelen H, Verhelst R, De Sutter P et al. (2012). Association between bacterial vaginosis and cervical intraepithelial neoplasia: systematic review and meta-analysis. PLoS One. 7(10): e45201. Epub 2012 Oct 2. https://doi.org/10.1371/journal.pone.0045201; PMid:23056195 PMCid:PMC3462776

11. Hilal Z, Rezniczek GA, Tettenborn Z, Hefler LA, Tempfer CB. (2016). Efficacy of Monsel solution after cervical biopsy: a randomized trial. J Low Genit Tract Dis. 20(4): 312-316. https://doi.org/10.1097/LGT.0000000000000234; PMid:27428608

12. Jiang YM, Chen CX, Li L. (2016, Jun 29). Meta-analysis of cold-knife conization versus loop electrosurgical excision procedure for cervical intraepithelial neoplasia. Onco Targets Ther. 9: 3907-15. https://doi.org/10.2147/OTT.S108832; PMid:27418835 PMCid:PMC4934869

13. Kietpeerakool C, Chumworathayi B, Thinkhamrop J, Ussahgij B, Lumbiganon P. (2017). Antibiotics for infection prevention after excision of the cervical transformation zone. Cochrane Database Syst Rev. 1(1): CD009957. https://doi.org/10.1002/14651858.CD009957.pub2; PMid:28109160 PMCid:PMC6464760

14. Kyrgiou M, Kalliala IE, Mitra A, Fotopoulou C, Ghaem-Maghami S, Martin-Hirsch PP et al. (2017, Jan 26). Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test. Cochrane Database Syst Rev. 1(1): CD009836. https://doi.org/10.1002/14651858.CD009836.pub2; PMid:28125861 PMCid:PMC6464319

15. Mardhia M, Effiana E, Irsan A, Natalia D, Rahmayanti S, Indarti J et al. (2018). Infections of Chlamydia trachomatis and Mycoplasma hominis as risk factors for abnormal cervical cells. Makara J Health Res. 22(1): 53-57. https://doi.org/10.7454/msk.v22i1.7965

16. Martin-Hirsch PP, Bryant A. (2013, Dec 4). Interventions for preventing blood loss during the treatment of cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2013(12): CD001421. https://doi.org/10.1002/14651858.CD001421.pub3; PMid:24302533 PMCid:PMC6513534

17. Masson L, Mlisana K, Little F, Werner L, Mkhize NN, Ronacher K et al. (2014, Dec). Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. Sex Transm Infect. 90(8): 580-587. Epub 2014 Aug 8. https://doi.org/10.1136/sextrans-2014-051601; PMid:25107710

18. National Center for Biotechnology Information. PubChem Compound Summary for Policresulen. URL: https://pubchem.ncbi.nlm.nih.gov/compound/Policresulen.

19. Ouh YT, Kim HY, Yi KW, Lee NW, Kim HJ, Min KJ. (2024). Enhancing cervical cancer screening: review of p16/Ki-67 dual staining as a promising triage strategy. Diagnostics (Basel). 14(4): 451. https://doi.org/10.3390/diagnostics14040451; PMid:38396493 PMCid:PMC10888225

20. Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F et al. (2020). 2019 ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 24(2): 102-131. https://doi.org/10.1097/LGT.0000000000000525; PMid:32243307

21. Prendiville W, Sankaranarayanan R. (2017). Colposcopy and Treatment of Cervical Precancer. IARC Technical Report No. 45. Lyon: International Agency for Research on Cancer.

22. Schiffman M, Doorbar J, Wentzensen N, de Sanjosé S, Fakhry C, Monk BJ et al. (2016). Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2: 16086. https://doi.org/10.1038/nrdp.2016.86; PMid:27905473

23. Sellors JW, Sankaranarayanan R. (2003). Colposcopy and treatment of cervical intraepithelial neoplasia: a beginners' manual. Lyon: International Agency for Research on Cancer.

24. Sharp L, Cotton S, Cochran C, Gray NM, Little J, Neal K et al. (2009). After-effects reported by women following colposcopy, cervical biopsies and LLETZ: results from the TOMBOLA trial. BJOG. 116(11): 1506-1514. https://doi.org/10.1111/j.1471-0528.2009.02263.x; PMid:19583712

25. Shi W, Zhu H, Yuan L, Chen X, Huang X et al. (2022). Vaginal microbiota and HPV clearance: a longitudinal study. Front Oncol. 12: 955150. https://doi.org/10.3389/fonc.2022.955150; PMid:36353544 PMCid:PMC9639776

26. Supplisson O, Tessandier N, Roussel M, Haim-Boukobza S, Burrel S et al. (2025, Jul). High-risk human papillomavirus cervical infection prevalence: a nationwide retrospective study comparing opportunistic and organised screening, France, 2020 to 2023. Euro Surveill. 30(28): 2400689. https://doi.org/10.2807/1560-7917.ES.2025.30.28.2400689; PMid:40682451 PMCid:PMC12273260

27. Swidsinski A, Mendling W, Loening-Baucke V, Ladhoff A, Swidsinski S et al. (2005). Adherent biofilms in bacterial vaginosis. Obstet Gynecol. 106; 5 Pt 1: 1013-1023. https://doi.org/10.1097/01.AOG.0000183594.45524.d2; PMid:16260520

28. Van de Wijgert JH, Borgdorff H, Verhelst R, Crucitti T, Francis S et al. (2014). The vaginal microbiota: what have we learned after a decade of molecular characterization? PLoS One. 9(8): e105998. https://doi.org/10.1371/journal.pone.0105998; PMid:25148517 PMCid:PMC4141851

29. Voidăzan ST, Dianzani C, Husariu MA, Geréd B, Turdean SG, Uzun CC et al. (2022, Jun 23). The Role of p16/Ki-67 Immunostaining, hTERC Amplification and Fibronectin in Predicting Cervical Cancer Progression: A Systematic Review. Biology (Basel). 11(7): 956. https://doi.org/10.3390/biology11070956; PMid:36101337 PMCid:PMC9312145

30. Waxman AG, Conageski C, Silver MI, Tedeschi C, Stier EA, Apgar B et al. (2017, Oct). ASCCP Colposcopy Standards: How Do We Perform Colposcopy? Implications for Establishing Standards. J Low Genit Tract Dis. 21(4): 235-241. https://doi.org/10.1097/LGT.0000000000000336; PMid:28953112 PMCid:PMC5659731

31. Wetcho T, Rattanaburi A, Kanjanapradit K. (2018, Jul). Quality of tissue from punch biopsy forceps vs. round loop electrode in colposcopically directed biopsy: a randomized controlled trial. J Gynecol Oncol. 29(4): e52. Epub 2018 Mar 12. https://doi.org/10.3802/jgo.2018.29.e52; PMid:29770623 PMCid:PMC5981104

32. Weng C, Xu J, Yang H, Deng P, Ou H, Xu Y et al. (2023). Efficacy of recombinant bovine basic fibroblast growth factor to reduce hemorrhage after cervical loop electrosurgical excision procedure. BMC Women's Health. 23(1): 385. https://doi.org/10.1186/s12905-023-02474-1; PMid:37479994 PMCid:PMC10362730